Clinical Trial Update: Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is investigating the impact of other oncogene mutations on anti-EGFR efficacy in left-sided RAS-wild type metastatic colorectal cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Snippet

Sponsor: City Clinical Oncology Hospital No 1 | Conditions: Colorectal Neoplasms, Chemotherapy Effect | Phase 3 | Status: RECRUITING